Aptamers against TLR4 to treat stroke2018-08-06
In the project also participate the IRYCIS Aptamer Group, led by Dr. Víctor M. González and M. Elena Martín, the Neurovascular Research Unit, directed by professors Ignacio Lizasoain and María Ángeles Moro and belonging to the University Institute of Research in Neurochemistry of the Madrid Complutense University and the Health Research Institute Hospital 12 de Octubre (i + 12) of Madrid, the Neurovascular Research Group of the Institute of Biomedicine of Seville (IBiS) and the biopharmaceutical company AptaTargets SL, participated by Aptus, dedicated to the preclinical and clinical development of innovative molecules based on aptamer technology. The work has recently been published in Molecular Therapy.
'La Caixa' and Inveready raise in Aptatargets2017-06-01
A Spanish public-private research, in which the biotechnology companies Aptus Biotech and AptaTargets and researchers from the IRYCIS-Ramón y Cajal Hospital and Universidad Complutense have participated, has given rise to a potential drug for the treatment of ischemic stroke, the second cause of Mortality in the general population and first in women, which may change the outlook of patients suffering from an ischemic episode. Caixa Capital Risc and Inveready have invested 2.7 million euros in the company AptaTargets to complete the preclinical phase and enter the phases of clinical trials I and II of this first drug candidate of the company.
Aptus Biotech at 4th Oxford symposium on aptamers2017-04-26
Aptus Biotech, represented by Dr. Ana García-Sacristán, Project Manager at the company, attends the 4th Oxford symposium on aptamers, Aptamers 2017.
APTUS PARTICIPATES IN THE 2016 RETOS PROGRAM2017-01-15
The Ministry of Economy and Competiveness has granted Aptus Biotech with funds from the National Research, Development and Innovation Programme oriented to Social Challenges, within the 2013-2016 National Plan for Scientific and Technical Research and Innovation. Aptus leads a Consortium of public and private entities (Instituto de Salud Carlos III de Madrid, Fundación Gaiker, Biokilab, Osasen Sensores, OSI HealthXXI and Lumiker Aplicaciones Tecnológicas) for the development of the CHIKTEST, a project aiming to develop innovative diagnostic tools for Tropical Diseases and specifically Chikungunya Virus, applying aptamers among other technologies.
ApTOLL GETS FUNDS FROM RETOS-2015 PROGRAM 2015-12-29
Aptus Biotech has received a new grant from the Spanish Ministry of Economy and Competitiveness within the State Program of Research, Development and Innovation (2013-2016). The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company AptaTargets and as research centers, are also participating the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.
REPRODUCIBILITY CRISIS: BLAME IT ON THE ANTIBODIES2015-05-21
"Antibodies are the workhorses of biological experiments, but they are littering the field with false findings. A few evangelists are pushing for change" . Nature 521, 274–276 (21 May 2015)
CAIXA CAPITAL SUPPORTS APTUS BIOTECH 2015-05-19
Aptus Biotech has received funding from Caixa Capital Risc (the Venture Capital from CaixaBank), with the aim of supporting the development of ApToll, an innovative therapy based on aptamer technology for treatment of Acute Stroke.
APTUS RECEIVES FUNDS FROM THE 2014 Retos 2014-12-10
The Ministry of Economy and Competiveness has granted Aptus Biotech with funds from the National Research, Development and Innovation Program oriented to Social Challenges, within the 2013-2016 National Plan for Scientific and Technical Research and Innovation. Aptus leads a Consortium of public and private entities (Vircell, CAB-CSIC-INTA and IRYCIS) and the project aims to develop an innovative diagnostic and genotyping system for the Hepatitis C Virus (HCV) based on AptaDetect technology.
AptaDetect platform presented in Barcelona2014-10-23
Our biosensing platform AptaDetect has been one of the selected projects at the Ist Entrepreneurs Fórum for In Vitro Diagnostics products, cellebrated in Barcelona by FENIN.
Aptus at Biospain20142014-09-26
Aptus Biotech was present at the Biospain2014 tradeshow. Latest results of the AptaDetect biosensing platform were presented at the Investment Fórum.
Aptus gets a Torres Quevedo grant2013-11-20
Aptus Biotech has been founded by the Spanish Ministry of Economy (MINECO) through the Torres Quevedo Program 2012 for hiring a postdoctoral scientist in the area of Biochemistry and Molecular Biology. The researcher will be in charge of a three years R&D plan to develop and improve the AptaDetect platform and its application in HCV diagnosis.
Aptus with the RiboRed Network2014-05-30
As part of our compromise to contribute to the R&D of the society, Aptus Biotech present their projects and future perspectives in the RNA Spanish network RIboRed.
Aptus participates in 2014 RETOS2014-01-30
Aptus participates in the 2014 RETOS programme of the MINECO (Spanish Ministry of Economy) in a consortium formed with Vircell, CAB (CSIC-INTA) and IRYCIS. The project intends to develop an innovative diagnostic system for HCV based in the AptaDetect technology.
CDTI supports Aptus R&D activities2013-11-30
CDTI supports Aptus R&D activities. CDTI is a Spanish public agency depending of the MINECO (Ministry of Economy) that supports financially outstanding R&D projects. CDTI funds will be invested in innovative applications using recently developed anti-Toll Like Receptors (TLR) aptamers.
Aptus receives funds from ENISA 2013-11-28
Aptus receives funds from ENISA (EmpresaNacional de Innovación SA). The public agency ENISA supports Spanish innovative firms aiming a growth phase. Aptus is currently developing capacities to create an aptamer catalogue and innovative applications based on these novel molecules.
Course on Aptamer Technology 20132013-11-14
Last October, took place the first edition of the course on Aptamers Technology, organized by the IRYCIS and sponsored by Aptus Biotech and the Madrid Science Park (PCM). The course was held in the facilities of IRYCIS-Hospital Ramón y Cajal in Madrid and included both lectures and practical sessions.
Aptamers targeting Leishmania2013-10-21
Researchers from Aptus Biotech and the IRYCIS-Ramon y Cajal Hospital have recently published the research article entitled “DNA Aptamers Selectively Target Leishmaniainfantum H2A Protein” in Plos One. The article show the ability of aptamers against LiH2A to recognize and purify the protein. These aptamers might be useful for LiH2A identification and also may be of potential application as diagnostic system and as a laboratory tool with purification purpose.
Aptus participates in European consortiu2012-02-28
Aptus Biotech participates in a European consortium for developing innovative Real-Time detection of pathogens in industrial cereal processing. The project brings together companies and research centers from four European countries. Aptus Biotech will apply aptamer technology to identify several types of toxins.
Aptus gets a Torres Quevedo grant2011-10-30
Aptus Biotech has been founded by the Spanish Ministry of Economy (MINECO) through the Torres Quevedo Program 2011 for hiring a postdoctoral scientist. The researcher will be a project manager of the ApTLR project to develop aptamers against Toll-like receptors (TLR).
Aptus at EXPOQUIMIA2011-10-30
Aptus has participated at the Biotech
Forum which was held during EXPOQUIMIA in Barcelona, where Dr. Víctor M. Gonzalez presented the aptamers technology and its applications and
Prof. Juan C. Vidal discussed about
using aptamers in biosensors.
Aptus participates in the 2011 INNPACTO program. The consortium led by Igen
Biotech intends to develop a diagnostic kit based on aptamers. Involving two research centers: IRYCIS in Madrid and CEREMET (metabolism research center)
belonging to the University of Barcelona. Also participating private companies
Janus developments and Biosystems, both from Barcelona.
Aptus completed the first capital call2011-05-02
Aptus Biotech has successfully completed the first capital call: with the first injection of capital, the company will carry out the R&D Plan for 2011 and 2012.